Objectives: The aim of the study was to evaluate the long-term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)-, darunavir/ritonavir (DRV/r)-, and lopinavir/ritonavir (LPV/r)-containing regimens. Methods: Data were analysed for 5678 EuroSIDA-enrolled patients starting a DRV/r-, ATZ/r- or LPV/r-containing regimen between 1 January 2000 and 30 June 2013. Separate analyses were performed for the following subgroups of patients: (1) ART-naïve subjects (8%) at ritonavir-boosted protease inhibitor (PI/r) initiation; (2) ART-experienced individuals (44%) initiating the new PI/r with a viral load (VL) ≤500 HIV-1 RNA copies/mL; and (3) ART-experienced patients (48%) initiating the new PI/r with a VL >500 copies/mL. Virological failure (VF) was defined as two consecutive VL measurements >200 copies/mL ≥24 weeks after PI/r initiation. Kaplan–Meier and multivariable Cox models were used to compare risks of failure by PI/r-based regimen. The main analysis was performed with intention-to-treat (ITT) ignoring treatment switches. Results: The time to VF favoured DRV/r over ATZ/r, and both were superior to LPV/r (log-rank test; P < 0.02) in all analyses. Nevertheless, the risk of VF in ART-naïve patients was similar regardless of the PI/r initiated after controlling for potential confounders. The risk of VF in both treatment-experienced groups was lower for DRV/r than for ATZ/r, which, in turn, was lower than for LPV/r-based ART. Conclusions: Although confounding by indication and calendar year cannot be completely ruled out, in ART-experienced subjects the long-term effectiveness of DRV/r-containing regimens appears to be greater than that of ATZ/r and LPV/r.

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe / J.R. Santos, A. Cozzi-Lepri, A. Phillips, S. De Wit, C. Pedersen, P. Reiss, A. Blaxhult, A. Lazzarin, M. Sluzhynska, C. Orkin, C. Duvivier, J. Bogner, P. Gargalianos-Kakolyris, P. Schmid, G. Hassoun, I. Khromova, M. Beniowski, V. Hadziosmanovic, D. Sedlacek, R. Paredes, J.D. Lundgren, M. Losso, M. Kundro, B. Schmied, R. Zangerle, I. Karpov, A. Vassilenko, V.M. Mitsura, D. Paduto, N. Clumeck, M. Delforge, E. Florence, L. Vandekerckhove, J. Begovac, L. Machala, D. Jilich, G. Kronborg, T. Benfield, J. Gerstoft, T. Katzenstein, N.F. Moller, L. Ostergaard, L. Wiese, L.N. Nielsen, K. Zilmer, J. Smidt, M. Ristola, I. Aho, J.-. Viard, P.-. Girard, C. Pradier, E. Fontas, J. Rockstroh, R. Schmidt, O. Degen, H.J. Stellbrink, C. Stefan, G. Fatkenheuer, N. Chkhartishvili, P. Gargalianos, G. Xylomenos, P. Lourida, H. Sambatakou, J. Szlavik, M. Gottfredsson, F. Mulcahy, I. Yust, D. Turner, M. Burke, E. Shahar, H. Elinav, M. Haouzi, D. Elbirt, Z.M. Sthoeger, A. D'Arminio Monforte, R. Esposito, I. Mazeu, C. Mussini, F. Mazzotta, A. Gabbuti, V. Vullo, M. Lichtner, M. Zaccarelli, A. Antinori, R. Acinapura, M. Plazzi, A. Castagna, N. Gianotti, M. Galli, A. Ridolfo, B. Rozentale, V. Uzdaviniene, R. Matulionyte, T. Staub, R. Hemmer, V. Ormaasen, A. Maeland, J. Bruun, B. Knysz, J. Gasiorowski, M. Inglot, A. Horban, E. Bakowska, R. Flisiak, A. Grzeszczuk, M. Parczewski, M. Pynka, K. Maciejewska, E. Mularska, T. Smiatacz, M. Gensing, E. Jablonowska, E. Malolepsza, K. Wojcik, I. Mozer-Lisewska, L. Caldeira, K. Mansinho, F. Maltez, R. Radoi, A. Panteleev, O. Panteleev, A. Yakovlev, T. Trofimora, E. Kuzovatova, E. Borodulina, E. Vdoushkina, D. Jevtovic, J. Tomazic, J.M. Gatell, J.M. Miro, S. Moreno, J.M. Rodriguez, B. Clotet, A. Jou, C. Tural, J. Puig, I. Bravo, P. Domingo, M. Gutierrez, G. Mateo, M.A. Sambeat, J.M. Laporte, K. Falconer, A. Thalme, A. Sonnerborg, L. Flamholc, A. Scherrer, R. Weber, M. Cavassini, A. Calmy, H. Furrer, M. Battegay, A. Kuznetsova, G. Kyselyova, B. Gazzard, A.M. Johnson, E. Simons, S. Edwards, M.A. Johnson, A. Mocroft, J. Weber, G. Scullard, A. Clarke, C. Leen, J. Gatell, B. Ledergerber, O. Kirk, L. Peters, C. Matthews, A.H. Fischer, A. Bojesen, D. Raben, D. Kristensen, K. Gronborg Laut, J.F. Larsen, D. Podlekareva, L. Shepherd, A. Schultze, R. Thiebaut, D. Burger. - In: HIV MEDICINE. - ISSN 1464-2662. - 19:5(2018), pp. 324-338. [10.1111/hiv.12581]

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe

A. D'Arminio Monforte;M. Galli;
2018

Abstract

Objectives: The aim of the study was to evaluate the long-term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)-, darunavir/ritonavir (DRV/r)-, and lopinavir/ritonavir (LPV/r)-containing regimens. Methods: Data were analysed for 5678 EuroSIDA-enrolled patients starting a DRV/r-, ATZ/r- or LPV/r-containing regimen between 1 January 2000 and 30 June 2013. Separate analyses were performed for the following subgroups of patients: (1) ART-naïve subjects (8%) at ritonavir-boosted protease inhibitor (PI/r) initiation; (2) ART-experienced individuals (44%) initiating the new PI/r with a viral load (VL) ≤500 HIV-1 RNA copies/mL; and (3) ART-experienced patients (48%) initiating the new PI/r with a VL >500 copies/mL. Virological failure (VF) was defined as two consecutive VL measurements >200 copies/mL ≥24 weeks after PI/r initiation. Kaplan–Meier and multivariable Cox models were used to compare risks of failure by PI/r-based regimen. The main analysis was performed with intention-to-treat (ITT) ignoring treatment switches. Results: The time to VF favoured DRV/r over ATZ/r, and both were superior to LPV/r (log-rank test; P < 0.02) in all analyses. Nevertheless, the risk of VF in ART-naïve patients was similar regardless of the PI/r initiated after controlling for potential confounders. The risk of VF in both treatment-experienced groups was lower for DRV/r than for ATZ/r, which, in turn, was lower than for LPV/r-based ART. Conclusions: Although confounding by indication and calendar year cannot be completely ruled out, in ART-experienced subjects the long-term effectiveness of DRV/r-containing regimens appears to be greater than that of ATZ/r and LPV/r.
antiretroviral therapy-experienced patients; antiretroviral therapy-naïve patients; atazanavir/ritonavir; darunavir/ritonavir; lopinavir/ritonavir; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Europe; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome
Settore MED/17 - Malattie Infettive
2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
hiv.12581.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 607.43 kB
Formato Adobe PDF
607.43 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/773953
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact